T-box protein 4 mutation causing pulmonary arterial hypertension and lung disease
Arnaud Maurac, Émilie Lardenois, Mélanie Eyries, Maria Rosa Ghigna, Isabelle Petit, David Montani, Anne Guillaumot, Brice Caput, François Chabot, Ari Chaouat
Source: Eur Respir J, 54 (2) 1900388; 10.1183/13993003.00388-2019
Disease area: Pulmonary vascular diseases
Abstract
Pulmonary arterial hypertension (PAH) is a progressive disease mainly characterised by a widespread obstruction of distal pulmonary arteries [1]. Untreated, this disease rapidly leads to right heart failure, then to death [2]. Heritable PAH (hPAH) represents about 30% of PAH cases, and this category includes familial forms with or without identified mutations, and sporadic forms carrying a mutation. The first genetic abnormalities discovered in hPAH were bone morphogenetic protein receptor-2 (BMPR2 ) mutations. Loss of function of this receptor results in proliferation of vascular smooth muscle cells and selection of endothelial cell clones resistant to apoptosis [3]. Since, several other mutations have been implicated in PAH. Mutation in the T-box protein 4 (TBX4) gene lead to an autosomal-dominant disorder called “small patella syndrome” or “coxopodopatellar syndrome”, characterised by patellar aplasia and abnormalities of the feet and pelvis [4]. Recently, TBX4 mutation has been reported in childhood-onset PAH [5] and, more rarely, in adults [6, 7].
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Arnaud Maurac, Émilie Lardenois, Mélanie Eyries, Maria Rosa Ghigna, Isabelle Petit, David Montani, Anne Guillaumot, Brice Caput, François Chabot, Ari Chaouat. T-box protein 4 mutation causing pulmonary arterial hypertension and lung disease. Eur Respir J, 54 (2) 1900388; 10.1183/13993003.00388-2019
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: